Search research articles
Contact Us
Filters
Showing results (161-170 of 304) with videos related to
Page
of 31
Sort By:
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association
|
March 24, 2022
Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study
Timothy J Williamson, Edward B Garon, Jenessa R Shapiro, et al.
Psychosomatic Medicine
|
March 4, 2024
Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden
Timothy J Williamson, Edward B Garon, Michael R Irwin, et al.
Canadian Medical Association Journal
|
December 17, 1977
Treatment of accidental hypothermia with peritoneal dialysis
L S Soung, L Swank, T S Ing, et al.
Lupus Science & Medicine
|
August 29, 2022
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort
Selin Cooper Blenkinsopp, Qinggong Fu, Yulia Green, et al.
Infection and Immunity
|
January 1, 1991
Effects of Bordetella pertussis infection on human respiratory epithelium in vivo and in vitro
R Wilson, R Read, M Thomas, et al.
Arthritis Care & Research
|
March 2, 2023
Reply
Michelle Petri, Daniel Joyce, Kristin Haag, et al.
Arthritis Care & Research
|
January 30, 2023
Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response
Michelle Petri, Daniel Joyce, Kristin Haag, et al.
The Lancet. Oncology
|
May 29, 2017
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian, Aaron E Lisberg, Krikor Bornazyan, et al.
Coronary Artery Disease
|
November 24, 2022
Coronary plaque progression is greater in systemic lupus erythematosus than rheumatoid arthritis
Jeff Moore, Suvasini Lakshmanan, Venkat Sanjay Manubolu, et al.
Cancer
|
May 19, 2012
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
Jonathan W Goldman, Isett Laux, Feng Chai, et al.
Page
of 31
Search research articles
Search
Showing results (161-170 of 304) with videos related to
Sort By:
Page
of 31
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association
|
March 24, 2022
Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study
Timothy J Williamson, Edward B Garon, Jenessa R Shapiro, et al.
Psychosomatic Medicine
|
March 4, 2024
Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden
Timothy J Williamson, Edward B Garon, Michael R Irwin, et al.
Canadian Medical Association Journal
|
December 17, 1977
Treatment of accidental hypothermia with peritoneal dialysis
L S Soung, L Swank, T S Ing, et al.
Lupus Science & Medicine
|
August 29, 2022
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort
Selin Cooper Blenkinsopp, Qinggong Fu, Yulia Green, et al.
Infection and Immunity
|
January 1, 1991
Effects of Bordetella pertussis infection on human respiratory epithelium in vivo and in vitro
R Wilson, R Read, M Thomas, et al.
Arthritis Care & Research
|
March 2, 2023
Reply
Michelle Petri, Daniel Joyce, Kristin Haag, et al.
Arthritis Care & Research
|
January 30, 2023
Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response
Michelle Petri, Daniel Joyce, Kristin Haag, et al.
The Lancet. Oncology
|
May 29, 2017
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian, Aaron E Lisberg, Krikor Bornazyan, et al.
Coronary Artery Disease
|
November 24, 2022
Coronary plaque progression is greater in systemic lupus erythematosus than rheumatoid arthritis
Jeff Moore, Suvasini Lakshmanan, Venkat Sanjay Manubolu, et al.
Cancer
|
May 19, 2012
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
Jonathan W Goldman, Isett Laux, Feng Chai, et al.
Page
of 31